FDA clears mRNA flu vaccine mFLUSIVA for ages 50-64

U.S. regulators have authorized an mRNA-based seasonal influenza vaccine, mFLUSIVA, for adults aged 50 to 64, officials said. The decision marks the first time the U.S. Food and Drug Administration has cleared mRNA technology for a seasonal flu shot.

Officials said the approval adds a new vaccination option for an age group often considered more vulnerable to influenza complications than younger adults. The authorization was supported by clinical trial evidence comparing mFLUSIVA with standard-dose influenza vaccines.

Clinical evidence behind the 50–64 approval

Officials said the FDA’s decision for people aged Officials said the FDA’s decision for people aged 50–64 relied on trials that enrolled 40,000 participants. In those studies, mFLUSIVA showed 26% higher efficacy than standard-dose alternatives, according to the source material. The FDA’s action also establishes different regulatory routes depending on age, officials said. Under this approach, adults 50–64 received full approval, while older adults are handled under a separate pathway. Accelerated approval route for adults 65 and older For adults aged 65 and older, the FDA granted accelerated approval, officials said. Under that framework, the manufacturer is required to conduct additional studies to confirm clinical benefit in the older population.

Drug Administration

The source material did not provide details on the timing or design of the confirmatory studies. As a result, it remains unclear when additional data could be generated and when the 65+ authorization might shift from accelerated approval to a more definitive status.

mRNA enters a recurring seasonal vaccination category

Officials described the clearance as notable because it expands mRNA into seasonal influenza immunisation, a long-standing U.S. vaccination program that is updated repeatedly over time. Unlike products tied to a single outbreak response, seasonal influenza vaccination is typically revisited on an annual cycle.

Supporters of the platform argue that mRNA design and manufacturing can allow faster updates to vaccine composition when influenza viruses change. In seasonal flu, they say this could help reduce vaccine-virus mismatch, which the source material characterises as a recurring operational challenge in influenza control.

Policy backdrop and international review status

The authorization comes as federal policy has recently shifted on funding for mRNA research programs, according to the source material. Officials framed the clearance as a product-by-product regulatory decision unfolding alongside a changing policy environment.

Outside the United States, mFLUSIVA is still under review in multiple jurisdictions, including Europe, Canada, and Australia, the source material says. No decisions by those regulators were cited in the provided information.

Officials said practical near-term effects for public health planners and healthcare providers will depend on how the two U.S. authorizations are implemented by age group and how quickly required studies in adults 65 and older are completed. The vaccine’s performance across influenza seasons and strains is also expected to be monitored as post-authorization evidence accumulates.